85 related articles for article (PubMed ID: 28179288)
1. Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells.
Murai S; Matuszkiewicz J; Okuzono Y; Miya H; DE Jong R
Anticancer Res; 2017 Feb; 37(2):437-444. PubMed ID: 28179288
[TBL] [Abstract][Full Text] [Related]
2. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
[TBL] [Abstract][Full Text] [Related]
4. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy.
Duan X; Mu M; Yan J; Bai L; Zhong L; Zhu Y; Pan H; Zhang M; Shi J
Int J Nanomedicine; 2018; 13():1443-1456. PubMed ID: 29563798
[TBL] [Abstract][Full Text] [Related]
6. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
7. The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL.
Jeong NY; Yoon YG; Rho JH; Lee JS; Lee SY; Yoo KS; Song S; Suh H; Choi YH; Yoo YH
Int J Oncol; 2011 Jun; 38(6):1597-604. PubMed ID: 21424121
[TBL] [Abstract][Full Text] [Related]
8. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
[TBL] [Abstract][Full Text] [Related]
9. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Timme CR; Gruidl M; Yeatman TJ
Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
11. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
14. siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs.
Lei XY; Zhong M; Feng LF; Zhu BY; Tang SS; Liao DF
Clin Exp Pharmacol Physiol; 2007; 34(5-6):450-6. PubMed ID: 17439414
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Tirado OM; Mateo-Lozano S; Notario V
Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
[TBL] [Abstract][Full Text] [Related]
16. Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells.
Rieger C; Huebner D; Temme A; Wirth MP; Fuessel S
Int J Oncol; 2015 Sep; 47(3):1121-30. PubMed ID: 26201840
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
18. [Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer].
Zhu HB; Huang XF; Hu JZ; Zhou W; Chen W; Chen LL; He C
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):245-9. PubMed ID: 18788624
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
20. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
